Peptides News and Research

RSS

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that the Office of Orphan Products Development of the US Food and Drug Administration (FDA) has granted orphan drug designation to the active ingredient SGX94 for the treatment of acute radiation syndrome (ARS).

16 Sep 2013

Kinder chemistry promises cleaner and safer pharmaceuticals with fewer side-effects

A new and kinder chemistry promises cleaner and subsequently safer pharmaceuticals with fewer side-effects. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".

16 Sep 2013

LifeSensors receives U.S. patent for development of novel DUB substrates

LifeSensors, Inc., a biotech company developing cutting-edge technologies for studying the ubiquitin pathway, has been awarded a U.S. patent for the development of novel, fluorescent di- and poly-ubiquitin deubiquitinase substrates (US 8,518,660).

16 Sep 2013

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory Epitope [HDM-SPIRE] based on Circassia’s ToleroMune technology).

12 Sep 2013

Rhythm Awarded $1.35M From Michael J. Fox Foundation

...

10 Sep 2013

Amino acid arginine improves treatment for type 2 diabetes

More than 371 million people worldwide suffer from diabetes, of whom 90% are affected by lifestyle-related diabetes mellitus type 2 (type 2 diabetes).

10 Sep 2013

Basic fibroblast growth factor can protect endplate in motor neurons of injured spinal cord

In current studies, the degeneration and protection measures in the distal end of the injured spinal cord and target organ muscle effector have scarcely been investigated. The distal end of the spinal cord and neuromuscular junction may develop secondary degenera-tion and damage following spinal cord injury because of the loss of neural connections.

7 Sep 2013

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

...

5 Sep 2013

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

ThromboGenics NV, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that it has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema.

5 Sep 2013

65 metabolites in urine simultaneously measured by clinical IEM-by-NMR screening study in Turkey

At the 12th International Congress of Inborn Errors of Metabolism (www.iciem2013.com), Bruker announces another milestone in the cost-effective use of NMR (nuclear magnetic resonance) spectroscopy screening as a clinical research tool for metabolic screening and small molecule in vitro diagnostics (IVD) research and validation.

4 Sep 2013

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Results from the START clinical study (Study of Thymoglobulin to Arrest Newly Diagnosed Type 1 Diabetes), led by Dr. Steve Gitelman (University of California, San Francisco) and sponsored by the Immune Tolerance Network, are published today in The Lancet Diabetes & Endocrinology.

28 Aug 2013

Study reveals role of cadherin receptor BT-R3 in killing action of Cry4B mosquito toxin

Researchers at The University of Texas at Dallas (UTD), led by Dr. Lee Bulla, have demonstrated for the first time the selective cytotoxicity of Bacillus thuringiensis subsp. israelensis Cry4B toxin is mediated by BT-R3.

27 Aug 2013

Ultimate DIY book for laboratory chemists in search of next generation medicines

Pharmaceuticals of the future will be fashioned using the human body's own chemical substances, proteins and peptides. And now, University of Copenhagen chemists have published the ultimate DIY book for laboratory chemists in search of this next generation of medicines.

23 Aug 2013

Research findings may lead to treatments for disorders triggered by circadian clock dysfunction

Overnight flights across the Atlantic, graveyard shifts, stress-induced insomnia are all prime culprits in keeping us from getting a good night's sleep. Thanks to new research from McGill University and Concordia University, however, these common sleep disturbances may one day be put to bed.

22 Aug 2013

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls.

20 Aug 2013

Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

Dermatology researcher Nicole Ward, PhD, has earned her third National Institutes of Health grant in a year - including two that scored in the first percentile. With this most recent award, an R21, she will investigate the role the nervous system plays in psoriasis - an inflammatory autoimmune disease characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin.

17 Aug 2013

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Aileron Therapeutics, Inc., a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary Stapled Peptide drug platform, announced today the publication of preclinical data on ATSP-7041, a potent and selective stapled peptide re-activator of the wild type p53 tumor suppressor protein.

17 Aug 2013

Researchers discover how common oral bacterium can contribute to colorectal cancer

Researchers from Case Western Reserve University School of Dental Medicine have discovered how a common oral bacterium can contribute to colorectal cancer, a finding that opens promising new research avenues for the development of approaches to prevent and treat the disease.

16 Aug 2013

LMU immunologists develop new technique to fight against tumors, autoimmune diseases

Immunologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the method to be developed further.

14 Aug 2013

New research opens door for development of treatments capable of stopping Alzheimer's disease

New research just out in the journal Science Translational Medicine opens the door for the development of treatments capable of stopping Alzheimer's disease (AD) before its first symptoms, that is to say before any crucial damage occurs. In fact, if AD is a devastating disorder it is also an extremely slow one; it takes more than 10 years for the first symptoms to appear making this preclinical period (pre-symptoms) the ideal time to intervene.

13 Aug 2013

Peptides News and Research

FDA grants orphan drug designation to Soligenix’s SGX94 for treatment of Acute Radiation Syndrome

Kinder chemistry promises cleaner and safer pharmaceuticals with fewer side-effects

LifeSensors receives U.S. patent for development of novel DUB substrates

Circassia: House dust mite allergy treatment meets primary endpoint in phase II clinical study

Rhythm Awarded $1.35M From Michael J. Fox Foundation

Amino acid arginine improves treatment for type 2 diabetes

Basic fibroblast growth factor can protect endplate in motor neurons of injured spinal cord

Thrombogenics, Bicycle Collaborate On Drugs Targeting Eye Diseases

ThromboGenics, Bicycle to develop and commercialize novel drugs for ophthalmic diseases

65 metabolites in urine simultaneously measured by clinical IEM-by-NMR screening study in Turkey

Results from Phase II START study published in The Lancet Diabetes & Endocrinology

Study reveals role of cadherin receptor BT-R3 in killing action of Cry4B mosquito toxin

Ultimate DIY book for laboratory chemists in search of next generation medicines

Research findings may lead to treatments for disorders triggered by circadian clock dysfunction

Clinical trial shows type-1 diabetes patients treated with teplizumab exhibit greater response to therapy

Dermatology researcher receives NIH grant to investigate role of nervous system in psoriasis

ATSP-7041 stapled peptide activates p53, suppresses tumor growth in animal models

Researchers discover how common oral bacterium can contribute to colorectal cancer

LMU immunologists develop new technique to fight against tumors, autoimmune diseases

New research opens door for development of treatments capable of stopping Alzheimer's disease

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News